Victrex plc (LON:VCT) Given Average Rating of “Hold” by Analysts

Shares of Victrex plc (LON:VCT) have been given a consensus rating of “Hold” by the six analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is GBX 720.83.

VCT has been the topic of a number of recent analyst reports. UBS Group reissued a “sell” rating and set a GBX 575 price target on shares of Victrex in a report on Monday. JPMorgan Chase & Co. lowered their price target on shares of Victrex from GBX 725 to GBX 625 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a GBX 725 price target on shares of Victrex in a report on Monday, April 13th.

Victrex Stock Performance

Shares of LON:VCT traded up GBX 0.54 during trading on Monday, hitting GBX 589.54. 794,701 shares of the stock traded hands, compared to its average volume of 737,339. The company has a quick ratio of 1.99, a current ratio of 3.01 and a debt-to-equity ratio of 11.30. The company has a fifty day moving average price of GBX 612.46 and a two-hundred day moving average price of GBX 644.88. Victrex has a 52-week low of GBX 515 and a 52-week high of GBX 882. The company has a market cap of £513.63 million, a price-to-earnings ratio of 18.54, a P/E/G ratio of 1.92 and a beta of 0.75.

Victrex (LON:VCT) last announced its quarterly earnings results on Monday, May 11th. The company reported GBX 17.20 earnings per share (EPS) for the quarter. Victrex had a net margin of 9.50% and a return on equity of 6.40%. The firm had revenue of £147.10 million for the quarter. As a group, equities analysts predict that Victrex will post 73.1078905 EPS for the current year.

Victrex Company Profile

Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.